LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity

Summary

Article discusses LB Pharmaceuticals' pharmaceutical development approach involving methyl groups and enantiomers, highlighting a potential $5 billion market opportunity. No specific clinical data, regulatory events, or financial metrics are provided.